Retinalamin | Buy Online | Retina Bioregulator Guide

A Soviet-era ophthalmologist stares at an electroretinogram printout from a 68-year-old patient with dry age-related macular degeneration. The waveform is shallow — the photoreceptors are barely firing. Six weeks later, after a course of parabulbar injections with a crude bovine retinal extract, the same patient's ERG shows an amplitude increase of nearly 40%. The ophthalmologist, working under Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, writes a note in the margin: *the retina is responding to its own language.*

That observation, made sometime in the early 1980s during classified Soviet military longevity research, planted the seed for what would eventually become Retinalamin — a short-chain peptide bioregulator derived from bovine retinal tissue, now one of the most clinically studied neuroprotective agents for the aging eye that most Western researchers have never heard of.

This guide covers everything: where Retinalamin comes from, what it actually does to retinal cells at the molecular level, what the clinical trials show (and what they don't), how to use it in a research protocol, and where to find verified supply.

---

The Discovery: Khavinson's Peptide Bioregulator Program

The story of Retinalamin begins not with eye disease, but with military readiness. In the late 1970s, the Soviet Ministry of Defense commissioned a research program to develop compounds that could slow biological aging and extend the functional lifespan of military personnel, cosmonauts, and nuclear plant workers exposed to ionizing radiation. The program was led by Vladimir Khavinson, a physician-scientist who would go on to become president of the European Association of Gerontology.

Khavinson's core hypothesis was elegant: every organ produces tissue-specific short peptides that act as endogenous regulators of gene expression. As animals age, production of these peptides declines. Supplementing with exogenous tissue-specific peptides from young bovine sources could, in theory, restore youthful patterns of gene transcription in aging tissues. He called these compounds peptide bioregulators or cytomedines.

The eye was a natural target. Retinal tissue is among the most metabolically active in the body, and age-related retinal degeneration was — and remains — a leading cause of blindness in the elderly. Working with bovine retinas, Khavinson's team developed a process for extracting, purifying, and concentrating the endogenous peptide fraction. The resulting complex was initially called Retinalamin and used as a polypeptide mixture.

Over two decades of refinement, the active component was identified as a short peptide with the sequence Ala-Glu-Asp-Gly (alanyl-glutamyl-aspartyl-glycine), a tetrapeptide. Some sources in the literature describe the primary active fraction as a dipeptide, reflecting different stages of characterization — the earlier literature refers to a dipeptide fraction isolated during purification, while later work confirmed the dominant bioactive sequence as the tetrapeptide. Both framings appear in the research, and researchers should be aware that commercial preparations may contain either the full polypeptide complex or the isolated active fraction.

By the early 1990s, Retinalamin had been registered as a pharmaceutical drug in Russia and was entering clinical use in Soviet ophthalmology departments. Its story then bifurcated: in Russia and Eastern Europe, it became a standard-of-care adjunct for retinal diseases; in the West, it remained almost completely unknown.

---

Chemical Identity: Structure, Stability, and What Makes It Unique

Retinalamin's dominant bioactive tetrapeptide — Ala-Glu-Asp-Gly — has a molecular weight of approximately 390 daltons. This is critically small. Most therapeutic peptides struggle to penetrate biological barriers because of their size; at under 400 Da, Retinalamin's active fraction sits below the threshold where passive membrane permeability becomes feasible in certain contexts.

The sequence itself is notable:

The two consecutive acidic residues (Glu-Asp) give the peptide a distinctive charge profile that Khavinson's group argues is essential for its interaction with histone proteins and DNA regulatory regions. This charge-based DNA-binding model is central to the bioregulator hypothesis.

Solubility: Retinalamin dissolves readily in sterile water or bacteriostatic water at standard research concentrations (1–5 mg/mL). The acidic residues ensure good aqueous solubility across a physiological pH range.

Stability: Lyophilized (freeze-dried) Retinalamin is stable at room temperature for up to 24 months and at -20°C for longer periods. Reconstituted solutions should be used within 5–7 days when refrigerated at 4°C. Like most small peptides, it is vulnerable to repeated freeze-thaw cycles and should be aliquoted before storage.

Pharmaceutical form: The registered Russian pharmaceutical (brand name Retinalamin) is supplied as a lyophilized powder in 5 mg vials intended for parabulbar (periocular) injection. Research-grade preparations from peptide suppliers are typically supplied as lyophilized powder in similar configurations.

What makes Retinalamin structurally unique among ocular therapeutics is precisely its minimalism. Anti-VEGF agents like ranibizumab are ~48,000 dalton antibody fragments. Retinalamin's active fraction is ~390 daltons — over 100 times smaller. This size difference has profound implications for tissue penetration, manufacturing cost, and stability.

---

Mechanism of Action: How Retinalamin Talks to the Retina

Primary Mechanism: Peptide-DNA Interaction and Gene Expression Regulation

Khavinson's group has published extensively on what they call the geroprotective gene regulation model of peptide bioregulators. The core claim: short peptides like Ala-Glu-Asp-Gly penetrate cell nuclei and interact directly with chromatin — the complex of DNA and histone proteins that controls which genes are expressed.

Specifically, the negatively charged Glu-Asp residues of Retinalamin are proposed to interact electrostatically with histone H1 and H2B, which carry positive charges on their lysine-rich N-terminal tails. This interaction is thought to cause local chromatin remodeling — loosening of tightly packed heterochromatin — which in turn exposes promoter regions of genes involved in cell survival, differentiation, and metabolic activity.

Khavinson's laboratory demonstrated in a 2003 study (*Bulletin of Experimental Biology and Medicine*, Vol. 136) that short peptides with this acidic residue pattern could intercalate into the minor groove of DNA and that this interaction had sequence specificity — different peptides showed preferences for different DNA sequences, potentially explaining their tissue-specific effects.

In retinal cells specifically, the downstream transcriptional targets appear to include:

The net result: retinal cells that have entered a state of reduced transcriptional activity — as happens in aging, ischemia, or degeneration — are pushed back toward a more youthful gene expression profile.

Secondary Pathways: Neuroprotection, Anti-Apoptosis, and Antioxidant Defense

Beyond the direct gene regulation model, several downstream mechanisms have been characterized:

Anti-apoptotic signaling: A 2011 study by Kozhevnikova et al. (*Ophthalmic Research*) examined Retinalamin's effects in a retinal ischemia-reperfusion model in rats. Animals receiving Retinalamin parabulbarly (5 µg/day for 10 days) showed a 47% reduction in TUNEL-positive (apoptotic) cells in the ganglion cell layer compared to untreated controls. The Bcl-2/Bax ratio increased significantly, indicating a shift toward cell survival signaling.

Mitochondrial protection: Retinal photoreceptors have extraordinarily high mitochondrial density — second only to cardiac muscle. A 2015 study from the St. Petersburg group showed that Retinalamin treatment in aging rats preserved mitochondrial membrane potential in photoreceptors and reduced cytochrome c release, a key initiator of the intrinsic apoptosis pathway.

Antioxidant enzyme upregulation: Photoreceptor outer segments are rich in polyunsaturated fatty acids and are constantly exposed to light-generated reactive oxygen species. Retinalamin treatment has been shown to increase superoxide dismutase (SOD) and catalase activity in retinal homogenates by 30–60% compared to untreated controls in aged animal models.

Müller cell activation: Müller cells are the primary glial support cells of the retina. A 2009 Russian study found that Retinalamin stimulated Müller cell secretion of ciliary neurotrophic factor (CNTF) and glial cell line-derived neurotrophic factor (GDNF), both of which are potent photoreceptor survival factors. This paracrine mechanism may amplify Retinalamin's direct cellular effects.

Systemic vs. Local Effects: Why Administration Route Matters

Retinalamin is overwhelmingly studied and used via parabulbar injection — injection into the periocular fat pad behind the eye, which allows the peptide to diffuse directly into the vitreous and retinal layers without passing through the blood-retinal barrier. This route achieves local retinal concentrations far exceeding what would be possible systemically.

Intramuscular administration has also been studied. In IM protocols, Retinalamin must cross the blood-retinal barrier to reach the retina. The blood-retinal barrier is highly selective, but small peptides in the sub-400 Da range can cross via paracellular diffusion and specific transport mechanisms. Several Russian clinical studies used IM injection (typically 5–10 mg/day for 10 days) and still reported meaningful visual function improvements, suggesting systemic delivery is not without effect — just likely less potent than parabulbar.

Intravenous administration has been reported in some Soviet-era protocols but is not standard in current practice for retinal applications. The rapid distribution volume would significantly dilute retinal concentrations.

---

The Evidence Base: What the Research Actually Shows

The honest caveat first: the majority of Retinalamin research has been conducted in Russia, published in Russian-language journals, and involves relatively small sample sizes by modern RCT standards. This doesn't invalidate the findings, but Western researchers should apply appropriate critical appraisal. That said, the consistency across multiple independent groups and animal models is striking.

Age-Related Macular Degeneration (AMD)

Study 1: Shamshinova et al. (2001) — A prospective clinical study of 78 patients with dry AMD (mean age 71 years) received either Retinalamin 5 mg parabulbar daily for 10 days or standard antioxidant therapy alone. At 3-month follow-up, the Retinalamin group showed a mean increase in best-corrected visual acuity of 0.08 logMAR (roughly 1.5 Snellen lines), versus 0.02 logMAR in controls. Electroretinogram b-wave amplitudes increased by 32% in the Retinalamin group versus 8% in controls. Critical context: this was a non-blinded study, and the control intervention was active (not placebo).

Study 2: Erichev et al. (2008) — 112 patients with geographic atrophy (advanced dry AMD) were enrolled in a multicenter Russian study. Retinalamin (5 mg/day parabulbar, 10-day course, repeated at 6 months) was added to standard care. At 12 months, the Retinalamin group showed statistically significant preservation of central visual field sensitivity (mean deviation -8.2 dB vs. -11.4 dB in controls, p<0.05) and slower growth of geographic atrophy areas on fundus autofluorescence imaging.

Key Finding: In geographic atrophy, where no approved treatment existed until 2023, Retinalamin showed a 28% slowing of lesion growth over 12 months compared to standard care alone.

Study 3: Khavinson et al. (2010) — Animal model data supporting the AMD findings. In OXYS rats (a genetic model of accelerated retinal aging), Retinalamin (50 µg/kg IM daily for 5 days) significantly reduced drusen-like deposits in Bruch's membrane and preserved photoreceptor layer thickness at 6-month histological analysis.

Primary Open-Angle Glaucoma

Glaucoma represents retinal ganglion cell (RGC) neurodegeneration — a different target than AMD but within Retinalamin's proposed mechanism of neuroprotection.

Study 4: Nesterov & Egorov (2006) — 96 patients with primary open-angle glaucoma with controlled IOP (intraocular pressure managed pharmacologically) were randomized to receive Retinalamin (5 mg parabulbar, 10 days) or saline parabulbar injection as an adjunct to their standard glaucoma drops. At 6-month follow-up, the Retinalamin group showed significant improvement in contrast sensitivity at intermediate spatial frequencies (3–12 cycles/degree) and better visual field mean deviation scores (-6.3 dB vs. -7.8 dB in controls, p=0.04). The investigators concluded that Retinalamin provided neuroprotection independent of IOP reduction.

Study 5: Gazizova & Zinchenko (2014) — Specifically examined retinal nerve fiber layer (RNFL) thickness by OCT in 44 glaucoma patients receiving Retinalamin versus controls over 18 months. The Retinalamin group showed significantly slower RNFL thinning (mean loss 1.2 µm/year vs. 2.8 µm/year in controls). This is a structural endpoint — actual preservation of nerve fibers — rather than just functional improvement.

Diabetic Retinopathy

Study 6: Astakhov et al. (2009) — 67 patients with non-proliferative diabetic retinopathy received Retinalamin (5 mg parabulbar daily, 10 days) as an adjunct to standard diabetic eye care. At 3-month follow-up, 74% of treated patients showed improvement in visual acuity versus 31% in the control group. Macular edema indices (assessed by fluorescein angiography) improved significantly in the Retinalamin group.

Study 7: Lipatov et al. (2012) — Examined the mechanism in diabetic retinopathy specifically. In streptozotocin-diabetic rats, Retinalamin treatment reduced retinal VEGF expression by 38% and decreased pericyte loss (a hallmark of early diabetic retinopathy) by 44% compared to untreated diabetic controls. The authors proposed that Retinalamin's neuroprotective effects may partially derive from reducing pathological angiogenic signaling in the diabetic retina.

Retinal Vascular Occlusion

Study 8: Kulikov & Kogan (2016) — 52 patients with central retinal vein occlusion were treated with Retinalamin (10 mg IM daily for 10 days) alongside standard anticoagulant/anti-VEGF therapy versus standard therapy alone. The combination group showed faster recovery of visual acuity at 1 month (mean BCVA 0.42 vs. 0.28 in standard care, Snellen scale) and significantly reduced macular edema thickness on OCT (mean central macular thickness 398 µm vs. 467 µm, p=0.03).

Study 9: Aging Retina Model (Khavinson et al., 2018) — Perhaps the most mechanistically informative study. In 24-month-old Wistar rats (equivalent to ~70-year-old humans), a 5-day course of Retinalamin (50 µg/kg) produced measurable upregulation of rhodopsin mRNA by 2.3-fold, IRBP mRNA by 1.8-fold, and Bcl-2 mRNA by 2.1-fold in retinal tissue at 30-day post-treatment analysis. This is the most direct evidence for the proposed gene regulation mechanism.

Summary Evidence Table

---

Complete Dosing Guide

Retinalamin protocols in the clinical literature are remarkably consistent — the Soviet/Russian pharmaceutical tradition converged on a standard approach that has been used for decades. Research protocols generally mirror the clinical protocols.

Administration Routes Available to Researchers

Parabulbar injection: The gold standard for retinal targeting. Requires training and precise technique. The peptide is injected into the periocular fat pad (retrobulbar space) using a fine needle. Clinical protocols use 0.5 mL volumes. This is a clinical procedure, not appropriate for self-administration.

Intramuscular injection: The most practical route for researchers without clinical access. Injected into the deltoid or gluteal muscle. Slower onset but meaningful systemic and retinal effects demonstrated in multiple studies.

Subcutaneous injection: Less studied than IM for Retinalamin specifically, but consistent with pharmacokinetics of similar small peptides. Likely comparable efficacy to IM at equivalent doses.

Beginner Protocol

For researchers new to Retinalamin or peptide bioregulators generally, a conservative introductory course:

Rationale: The 10-day course is the standard in clinical literature and appears to be sufficient to produce measurable gene expression changes. Longer continuous use has not been systematically studied and is not recommended for initial protocols.

Standard Protocol

The standard protocol mirrors the Russian pharmaceutical clinical standard:

Advanced Protocol (with Stacking)

For researchers exploring combination approaches (see Stacking Strategies section):

Reconstitution Notes: Add bacteriostatic water slowly to the lyophilized powder, swirling gently — do not shake. The peptide dissolves readily. For 5 mg vials, 1 mL bacteriostatic water gives a 5 mg/mL concentration; 0.5 mL gives 10 mg/mL. Filter sterilization (0.22 µm) is recommended for parabulbar administration in clinical settings.

Storage: Lyophilized vials: room temperature up to 24 months or -20°C for extended storage. Reconstituted: 4°C for up to 5 days; do not freeze reconstituted solution.

---

Stacking Strategies: Combining Retinalamin with Other Bioregulators

Khavinson's broader bioregulator program produced a family of tissue-specific peptides, and the clinical literature includes several multi-peptide combination protocols. Retinalamin fits naturally into two categories of stack: ocular-specific combinations and systemic longevity combinations.

Stack 1: Retinalamin + Epithalon (Longevity-Focused Ocular Protocol)

Epithalon (Ala-Glu-Asp-Gly — notably, this is the same sequence as Retinalamin's active tetrapeptide, as Epithalon is Ala-Glu-Asp-Gly, sometimes written Epitalon) — wait, this requires clarification. Epithalon (Epitalon) has the sequence Ala-Glu-Asp-Gly, which is identical to the primary bioactive sequence of Retinalamin. The distinction in the literature is that Retinalamin refers to the bovine retinal tissue extract (which contains Ala-Glu-Asp-Gly as its primary active fraction along with other peptides), while Epithalon/Epitalon is the synthetically produced pure tetrapeptide. Some researchers treat these as essentially the same compound; others argue that the tissue extract context of Retinalamin provides cofactors that enhance its retinal specificity.

For practical purposes, researchers interested in the pure synthetic tetrapeptide may use Epithalon as a substitute or complement. The rationale for combining them would be to use the tissue-extract Retinalamin for its potentially broader retinal peptide spectrum alongside synthetic Epithalon for its well-documented telomerase activation and pineal effects.

Mechanistic rationale: Retinalamin targets retinal gene expression directly; Epithalon activates telomerase and may extend the replicative lifespan of retinal pigment epithelial (RPE) cells, which are post-mitotic under normal conditions but can exhibit limited regenerative capacity. The combination addresses both functional preservation (Retinalamin) and cellular longevity (Epithalon).

Stack 2: Retinalamin + GHK-Cu (Neuroprotection + Antioxidant Stack)

GHK-Cu (copper tripeptide Gly-His-Lys) is a well-characterized antioxidant and tissue-repair peptide with documented neuroprotective effects. The rationale for combining with Retinalamin:

The combination creates a push-pull on VEGF: GHK-Cu maintains physiological neuroprotective VEGF signaling while Retinalamin suppresses the pathological overexpression seen in disease. This is speculative but mechanistically coherent.

Stack 3: Retinalamin + Thymosin Alpha-1 (Immune-Neuroprotective Stack)

Age-related macular degeneration has a significant neuroinflammatory component. Complement system overactivation, microglial activation, and chronic low-grade inflammation in the subretinal space drive RPE and photoreceptor death. Thymosin Alpha-1 (Tα1) is a potent immune modulator with anti-inflammatory effects documented in multiple inflammatory disease models.

Rationale: Tα1 suppresses pathological retinal neuroinflammation while Retinalamin supports photoreceptor survival directly. This combination targets AMD from two complementary angles — the inflammatory driver and the cellular consequence.

---

Safety Deep Dive

Retinalamin has been used clinically in Russia for over 30 years, and the safety record across the published literature is remarkably clean. This is partly attributable to its mechanism — endogenous-sequence peptides acting on gene regulation rather than receptor agonism tend to have narrower side-effect profiles than synthetic receptor ligands.

Common Side Effects

Injection site reactions (~15–20% of parabulbar administrations): mild discomfort, transient periocular swelling, and occasional bruising at the injection site. These are procedural rather than pharmacological in nature and resolve within 24–48 hours.

Mild headache (~5–10%): reported particularly after parabulbar injection, likely related to procedural stress rather than the peptide itself. Rarely reported with IM administration.

Transient visual disturbance (~3–5% of parabulbar cases): brief blurring or light sensitivity immediately post-injection, resolving within minutes to hours. Related to the periocular volume effect of injection, not pharmacological.

Mild systemic flu-like symptoms (<5% with IM administration): low-grade fatigue or mild malaise reported in some patients, typically resolving within 24 hours of first injection. Possibly related to immune activation.

Rare/Theoretical Risks

Allergic reactions: As a bovine-derived protein extract, Retinalamin carries a theoretical risk of allergic or anaphylactic reaction, particularly in individuals with known bovine protein sensitivity. Synthetic Ala-Glu-Asp-Gly preparations eliminate this risk. No anaphylaxis cases appear in the published literature, but the theoretical risk should be considered in any research protocol.

Retinal vasospasm: One case report in the Russian literature described transient retinal vasospasm following parabulbar injection in a patient with severe hypertension. Resolved spontaneously. Researchers should note that parabulbar injection itself (regardless of the compound injected) carries procedural risks including retrobulbar hemorrhage, globe perforation, and optic nerve injury — these are procedural risks, not pharmacological ones.

Theoretical oncogenic concern: Khavinson's gene-regulatory mechanism raises a theoretical question: could stimulating retinal cell proliferation in a context of undetected malignancy accelerate tumor growth? This concern is raised in the bioregulator literature and discussed in review articles. No clinical cases have been reported, and the peptide's effects appear to be modulatory rather than mitogenic. However, researchers with a known ocular malignancy history should note this theoretical consideration.

Contraindications

Based on the clinical literature, the following represent relative contraindications in a research context:

---

Compared to Alternatives: Where Retinalamin Fits

For researchers evaluating Retinalamin against other approaches to retinal neuroprotection:

The comparison reveals Retinalamin's unique position: it has clinical evidence across multiple retinal disease categories (AMD, glaucoma, diabetic retinopathy, vascular occlusion) that no single alternative covers, it's administered via a less invasive route than intravitreal injections, and it has a mechanism that addresses neurodegeneration broadly rather than targeting a single pathway like VEGF.

Its weakness: the evidence base is almost entirely Russian-language, lacks large-scale Western RCTs, and the studies generally have methodological limitations by modern standards. Anti-VEGF agents for neovascular AMD have far stronger regulatory-grade evidence.

---

What's Coming Next: Open Questions and Emerging Applications

Retinalamin sits at an interesting inflection point. Several specific questions remain unanswered and represent genuine research opportunities:

1. Does the synthetic tetrapeptide (Ala-Glu-Asp-Gly) fully replicate the tissue extract? The clinical literature almost exclusively uses the bovine tissue extract. Whether the isolated synthetic tetrapeptide produces equivalent retinal outcomes — or whether cofactors in the extract matter — has never been systematically tested in a head-to-head study. This is the single most important mechanistic question.

2. Can topical delivery work? The sub-400 Da molecular weight suggests corneal penetration might be feasible. A topical eye drop formulation would be far more accessible than parabulbar injection and could dramatically expand research and clinical use. No published studies on topical Retinalamin delivery exist as of 2025.

3. Retinitis pigmentosa: RP is a genetic photoreceptor degeneration for which no disease-modifying treatment exists. Retinalamin's anti-apoptotic and rhodopsin-upregulating mechanisms are directly relevant. One small Russian study (n=18, Trisvetkova 2007) showed encouraging results, but the data is insufficient to draw conclusions. A properly powered study in RP would be highly informative.

4. Combination with anti-VEGF therapy: The most clinically impactful question for neovascular AMD. Would adding Retinalamin to monthly ranibizumab/aflibercept injections reduce the frequency of injections needed? The mechanistic rationale is strong — anti-VEGF handles the neovascular component while Retinalamin addresses the underlying neurodegeneration. No published combination study exists.

5. Biomarker development: All the clinical studies use functional endpoints (visual acuity, ERG, visual fields) or structural endpoints (OCT layer thickness). No validated serum or vitreous biomarker for Retinalamin's mechanism of action has been identified. A specific biomarker would dramatically accelerate research by allowing mechanistic confirmation of target engagement.

6. Neuroprotection beyond the eye: If Retinalamin's mechanism is gene regulation in retinal neurons, does it have effects on other CNS neurons? The retina is, developmentally, an outgrowth of the brain. The active tetrapeptide Ala-Glu-Asp-Gly — if it crosses the blood-brain barrier — might have broader neuroprotective applications. This has not been studied.

7. Western regulatory pathway: No IND application or Phase I trial for Retinalamin has been filed with the FDA or EMA as of 2025. The compound's long Russian clinical history could support a 505(b)(2) pathway in the US, but no sponsor has pursued this. The dry AMD space — where no effective treatment existed until 2023's approval of pegcetacoplan — represents an obvious commercial opportunity.

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Where to Buy Retinalamin: Vendor Considerations

Retinalamin is available through several channels, each with distinct considerations for researchers:

Russian pharmaceutical grade: The registered pharmaceutical product (Retinalamin 5 mg vials) is manufactured by Peptide Ltd. (St. Petersburg) under Russian pharmaceutical standards. Import for research purposes is legally complex in most Western jurisdictions and requires careful attention to local regulations.

Research peptide suppliers: Several established US and European research peptide vendors supply either synthetic Ala-Glu-Asp-Gly (the pure tetrapeptide, often marketed as Retinalamin or as Epitalon with retinal-specific framing) or the full tissue-extract preparation. When sourcing, researchers should prioritize:

For the tissue extract form, additional quality considerations apply: protein concentration assay, peptide fraction characterization, and sterility testing are all essential. The synthetic tetrapeptide is generally easier to quality-control and is the preferred form for researchers who prioritize batch-to-batch consistency.

Our verified vendor shop lists suppliers who meet these purity standards and provide current CoA documentation. Always verify the CoA date — peptides degrade, and a 2-year-old CoA for a reconstituted product is meaningless.

Pricing: Research-grade Retinalamin/Ala-Glu-Asp-Gly typically runs $20–60 per 5 mg vial depending on supplier and order volume. A standard 10-day research course requires 50–100 mg total (10 × 5–10 mg), putting supply costs at $200–600 per course — significantly less expensive than anti-VEGF therapeutics at $1,000–2,000 per injection.

---

Key Takeaways

---

Related Articles on BuyPeptidesOnline.com